BioSpace News Archive

Quantzig, a leading analytics advisory firm that delivers customized analytics solutions, has announced the completion of its free resource that highlights how sales force effectiveness is reinventing the pharma industry in the United States.

Imbed Biosciences, Inc. announced that it has been awarded a $1.5 million two-year Small Business Innovation Research grant from the National Institute for Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health.

Cellular Biomedicine Group, Inc. announced that a drug application* for its off-the-shelf autologous adipose-derived mesenchymal progenitor cell ReJoin® therapy for Knee Osteoarthritis has been accepted for a Phase II clinical trial in China.

According to Coherent Market Insights, the global assistive reproductive technology market was valued at US$ 23.6 Billion in 2018, and is projected to exhibit a CAGR of 5.3% over the forecast period.

People enrolled in Blue Shield of California Promise Health Plan’s Medicare Advantage plans can receive in-network care from PIH Health, as of October 1, 2019.

New SCAPE 2.0 system can serve as a critical tool to advance science and medicine

Eisai Inc. announced new effectiveness and safety data from the Phase 3 clinical development program for lemborexant, an investigational agent for sleep-wake regulation, which is currently being studied for the treatment of insomnia, a sleep-wake disorder, and for Irregular Sleep-Wake Rhythm Disorder (ISWRD) in patients with Alzheimer’s disease (AD) dementia.

LivaNova PLC announced the first patient enrolled in “A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression”.

Investment will help advance development of the only gene therapy technology offering resistance to pre-existing antibodies, enhanced gene delivery and the potential for repeat dosing.

Study in The Lancet successfully demonstrated endpoints of identifying both vulnerable patients and vulnerable plaques that are at significantly higher risk for subsequent major adverse cardiovascular events